Merck and Parexel form biosimilar alliance

teaser

Merckand Parexel International have entered into a strategic alliance thatwill see the CRO provide global clinical development services fordesignated biosimilar candidates to Merck BioVentures, a division ofMerck.

The agreement also establishes a dedicated Merck BioVentures unit within the Parexel organisation.

↓Article continues below this sponsored advert↓

Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.

Agenda Register

↑Advertisement↑

MichaelKamarck, president of Merck BioVentures, says: “This agreementpositions Merck BioVentures for success with an industry leadingpartner that has the expertise and resources to conduct clinicaldevelopment of our diverse portfolio of candidates to allow timelydelivery of products to the marketplace.”

No further details of the agreement have been announced.

InDecember 2008, Merck established the bioventures division in December2008 to capitalise on its biologics manufacturing capabilities toproduce follow-on biologics.